Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our group is currently studying in detail the phenotype and function of type 17 responses in AS. 

The type 17/23 axis is now an important target for therapeutic drug and antibody development. We are also working on small molecule inhibitors of ERAP1, of the transcription factor ROR gamma T and of the (epigenetic) bromodomain readers and transcriptional co-activators CBP and p300. Our data show that all can inhibit Type17 responses in vitro.